|
CA2616608A1
|
|
Ep4 receptor agonist, compositions and methods thereof
|
|
WO2005070883A1
|
|
Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
|
|
CA2552713A1
|
|
Cathepsin cysteine protease inhibitors
|
|
WO2005066159A1
|
|
Cathepsin cysteine protease inhibitors
|
|
CA2548600A1
|
|
Cathepsin cysteine protease inhibitors
|
|
WO2005056582A1
|
|
Ptp1b photoprobes
|
|
US7019022B2
|
|
Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
|
|
WO2005029080A1
|
|
Whole cell assay for inhibitors of cathepsin k
|
|
CN1842515A
|
|
Cathepsin inhibitors
|
|
WO2005019161A1
|
|
Cathepsin cysteine protease inhibitors
|
|
AU2004240705A1
|
|
Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
|
|
AU2004229507A1
|
|
Polymorphic form of montelukast sodium
|
|
EP1594819A1
|
|
Irreversible caspase-3 inhibitors as active site probes
|
|
EP1592419A1
|
|
Use of phosphodiesterase-4 inhibitors as enhancers of cognition
|
|
AU2003283096A1
|
|
Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
|
|
WO2004039807A1
|
|
Pyridopyrrolizine and pyridoindolizine derivatives
|
|
CN1732171A
|
|
Pyridopyrrolizine and pyridoindolizine derivatives
|
|
EP1558602A2
|
|
2-pyrrolidones as ep4 receptor agonists
|
|
WO2004037813A1
|
|
Pyrrolidin-2-on derivatives as ep4 receptor agonists
|
|
AU2003278039A1
|
|
Nitric oxide releasing selective cyclooxygenase-2 inhibitors
|
